TAmiRNA presenting miND® NextGen sequencing opportunities to joint metabolics and xenobiotics conference

Vienna, Austria: Biotech and diagnostic innovator TAmiRNA will be a significant contributor to the inaugural joint European meeting of the ISSX and DMDG respectively focused on xenobiotics and drug metabolics.

During Day three of the combined meeting in Hertfordshire, England, TAmiRNA CEO and co-founder Dr. Matthias Hackl will take part in the discussions of Symposium 4: ‘MicroRNAs as Biomarkers of Clinical Drug-induced Organ Injury’ (Tuesday, June 13, 1000-1200 hrs).

miND® spike ins

Dr. Hackl’s presentation ‘miRNA Biomarker Development: Pitfalls and Best Practices for Discovery and Validation’ will highlight the increasing scope to apply TAmiRNA’s recently developed MicroRNA Next-Generation Sequencing Discovery (miND®) technology and associated miND® spike-ins to identify novel circulating MicroRNA Biomarkers of CNS and other organ damage, as well as comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs).

These opportunities will be further amplified in a TAmiRNA poster ‘Identification of novel circulating MicroRNA Biomarkers of Central Nervous System Damage by absolute quantitation using an Assay’, authored by Senior Scientist  Dr. Kseniya Khamina-Kotisch.

Quality control applications

Together, these contributions will show different aspects of the significance of the development of the miND® Next Generation Sequencing Discovery platform and its spike-in that serves for quality control and absolute normalization. This spike-in allows conversion of read counts to copies/µl total RNA and reduce bias originating from variation in RNA composition between samples.

Dr. Hackl commented: “We aim to show how the miND® product with its seven unique core sequences mixed in specific proportions can cover a wide range of endogenous microRNAs, representing up to 65,536 possible sequences of the 21 nucleotides (nts) that can be detected in the NGS data along with the endogenous small RNAs.”

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. TAmiRNA currently commercialized hepatomiR® under the CE-IVD mark for the diagnosis of liver function in liver cancer patients.

For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency.

More information available at: www.tamirna.com

About ISSX & DMDG 2023

For 2023, the International Society for the Study of Xenobiotics (ISSX) will combine its 16^th European Annual Meeting with the annual meeting of the international Drug Metabolism Discussion Group (DMDG).

The US-based ISSX offers an international forum for the exchange of knowledge among individuals interested in the study of xenobiotics and other related disciplines, while the DMDG, based in the UK, is an informal worldwide association for scientists engaged in research and development within the drug metabolism, pharmacokinetics and related disciplines of the pharmaceutical industry.

This first combined meeting of the two organizations will be a four-day event opening June 11 at the University of Hertfordshire , north of London. The meeting will provide a unique opportunity for researchers to gather and exchange ideas and expertise in the related fields of metabolics and xenobiotics.

The event is jointly organized by ISSX and DMDG with further information at: https://issx2023.org/issx-dmdg/invitation-to-attend

Resources

Click on TAmiRNA MiND Next Generation Sequencing  for further information.